Treating p53-mutated human tumors with p63 activators: Tumor suppressor MiRNA miR-335 increases the expression of tumor suppressor p53 homologue TA-p63 via up regulation of its target gene, 31/May/2014, 5.21 am

MiRNA-based therapy for glucose intolerance and insulin resistance: MiR-802 promotes ß-cell mass and function via down regulation of its target gene, 31/May/2014, 5.08 am
May 30, 2014
Therapeutic Insights into regulatory mechanisms that activate Detoxification: C/EBP-β increases the expression of antioxidant protein Nrf2/NFE2L2 via down regulation of its target gene, 31/May/2014, 5.27 am
May 30, 2014
Show all

Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Treating p53-mutated human tumors with p63 activators: Tumor suppressor MiRNA miR-335 increases the expression of tumor suppressor p53 homologue TA-p63 via up regulation of its target gene. This data suggests that miR-335, by suppressing the expression of its down steam target gene, it will increase the transcriptional activity of tumor suppressor p53  homologue TA-p63. Given that tumor suppressor p53 is mutated in more than 50% of different human cancers, this study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human cancer can be cured by activating its un-mutated homologous proteins.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan,Treating p53-mutated human tumors with p63 activators: Tumor suppressor MiRNA miR-335 increases the expression of tumor suppressor p53 homologue TA-p63 via up regulation of its target gene, 31/May/2014, 5.21 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.